Free tool
FAERS Monitor: Oxbryta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 213137 or its brand name (Oxbryta, Voxelotor). Reports on generic versions are filed under their own applications.
Reports
22,311
Serious
9,624
43% of reports
Hospitalization
7,860
Death reported
419
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- sickle cell anaemia with crisis11,220
- product dose omission issue5,172
- diarrhoea3,187
- off label use2,419
- nausea2,017
- headache1,691
- abdominal pain upper1,171
- pain1,086
- therapy cessation1,040
- fatigue1,008
- abdominal discomfort970
- therapy interrupted901
- vomiting833
- haemoglobin decreased753
- abdominal pain627
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 3,384 |
| 2021 | 3,536 |
| 2022 | 9,276 |
| 2023 | 4,504 |
| 2024 | 1,436 |
| 2025 | 142 |
| 2026 | 30 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,848 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sickle cell anaemia with crisisSignal | 11,220 | 2322.0 | 2249.2 | 7,521,204 |
| therapy cessationSignal | 1,040 | 19.5 | 18.3 | 17,882 |
| product dose omission issueSignal | 5,172 | 16.9 | 16.5 | 76,861 |
| therapy interruptedSignal | 901 | 12.0 | 11.3 | 9,012 |
| haemoglobin decreasedSignal | 753 | 7.0 | 6.5 | 3,825 |
| abdominal discomfortSignal | 970 | 5.5 | 5.1 | 3,553 |
| abdominal pain upperSignal | 1,171 | 5.4 | 5.1 | 4,196 |
| diarrhoeaSignal | 3,187 | 4.7 | 4.5 | 9,440 |
| off label useSignal | 2,419 | 2.6 | 2.5 | 2,496 |
| headacheSignal | 1,691 | 2.5 | 2.4 | 1,631 |
| abdominal painSignal | 627 | 2.5 | 2.4 | 591 |
| nauseaSignal | 2,017 | 2.4 | 2.3 | 1,716 |
| vomiting | 833 | 1.7 | 1.6 | 229 |
| pain | 1,086 | 1.7 | 1.6 | 298 |
| fatigue | 1,008 | 1.2 | 1.1 | 42 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.